Plain-English translation of NCT06660667 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing , a new treatment given as a single injection directly into the eye for people with neovascular age-related macular degeneration (wet AMD), a serious eye condition that damages central vision. The study will first test different doses to find the safest and most effective amount, then expand to confirm how well the treatment works. Participants will be closely monitored for up to 5 years to see if one injection can improve their vision and how long the benefits last.
Wet AMD is a leading cause of vision loss in older adults, and while current treatments require regular eye injections over time, this medication is designed to provide lasting benefit from just a single dose. The trial aims to see if this approach can reduce the treatment burden while maintaining or improving vision for people with this condition.
You likely qualify if…
You likely don't qualify if…
You will receive a single injection of the medication into your eye on the first day of the trial. After that, you will have regular follow-up visits over 12 months to check your vision, eye health, and for any side effects. The trial then continues with extended follow-up visits through year 5 to monitor how long the treatment works and ensure it remains safe. In total, you'll be involved in the study for up to 5 years with periodic eye exams and vision tests.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States